<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725085</url>
  </required_header>
  <id_info>
    <org_study_id>2012-MUC-PMS-IN</org_study_id>
    <nct_id>NCT03725085</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion</brief_title>
  <official_title>An Open Label, Multicentric Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi- Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reckitt Benckiser LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an open label, multicentric, non-comparative, single arm prospective post marketing
      surveillance (PMS) study to evaluate the safety and tolerability of Mucinex™ (GGE, 600 mg ER
      bi-layer tablets, taken as 1200 mg BID dose) in the treatment of otherwise healthy patients
      with symptoms of cough, thickened mucus and chest congestion due to URTI. Symptomatic
      patients who visited the outpatient department of hospitals and clinics or general physicians
      and had agreed to participate in this study were screened and enrolled into the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2015</start_date>
  <completion_date type="Actual">October 16, 2015</completion_date>
  <primary_completion_date type="Actual">October 16, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs), Type of AE(s) and Frequency of AE(s)</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>Treatment Emergent Adverse Event (TEAE) are events occurring after the first dose of study medication.
Frequency of AE(s) - the total Number of Events
Type of AE(s) - Serious TEAE and Non serious TEAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Affected With Adverse Events</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>Proportion of patients with AE(s) - Number of Subjects affected with Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events by Severity, Seriousness and the Relationship of AE(s) to Treatment</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>Intensity determined. Mild = AE did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Relationship to Investigational Medicinal Products (IMP) Unassessable/Unclassified = Insufficient information to be able to make an assessment Conditional/ Unclassified = Insufficient information to make an assessment at present Unrelated = No possibility that the AE was caused by the IMP Unlikely = Slight, but remote, chance that the AE was caused by the IMP, but the balance of judgment was that it was most likely not due to the IMP.
Possible = Reasonable suspicion that the AE was caused by the IMP Probable = Most likely that the AE was caused by the IMP Certain = AE was definitely caused by the IMP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Assessment of the Study Medication by End of Study Patient Questionnaire</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>End of Study Patient Questionnaire is a questionnaire provided to the patients for overall assessment of the study medication at the end of study visit.
Satisfied(stfd) Dissatisfied(Dstfd)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Assessment of the Study Medication by End of Study Investigator Questionnaire</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>End of Study Investigator Questionnaire is a questionnaire provided at the end of study visit to the investigator (or sub-investigator as applicable) for overall assessment of the study medication across all patients treated by them.
End of study investigator questionnaire was collected from 9 investigators.
Mostly Satisfied(MS) Satisfied(Stfd) Very Satisfied(VS) Chest Congestion(CC) Chesty Cough(CCO) Difference(Diff) Between(b/w) Somewhat Agree(SA) Strongly Agree(StA) Upper respiratory tract infection(URTI) Optimal dosage(Opt dos) Cough preparations Available(CPA)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">552</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 tablets of Mucinex™ (GGE, 600 mg ER bi-layer tablets, taken as 1200 mg BID dose) every 12 hours (twice daily, in the morning and the evening) orally with a full glass of water for 7 days.
GGE = Guaifenesin
BID = Twice in a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucinex™ extended-release (SE)</intervention_name>
    <description>2 tablets of Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)</description>
    <arm_group_label>Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)</arm_group_label>
    <other_name>Guaifenesin bi-layer tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients were eligible for enrolment in the study if they fulfilled the following criteria:

          1. Males and females (non-pregnant) patients of ≥ 18 years of age.

          2. Otherwise healthy patients suffering from cough with symptoms of thickened mucus and
             chest congestion and a diagnosis of any one of the following:

               -  Acute Bronchitis

               -  Upper Respiratory Tract Infections (URTI) such as naso-pharyngitis

               -  Sinusitis

          3. Females of child bearing potential:

               1. Must have used efficacious and reliable method of contraception during the entire
                  duration of the study {e.g. double barrier methods (e.g., condom and
                  spermicidal); intrauterine device (IUD) } or remained sexually inactive
                  throughout the study*.

               2. Must have had a negative urine pregnancy test (UPT) at Screening/Baseline (test
                  must have a sensitivity of at least 25 mIU/mL for HCG).

               3. Must have been non-lactating.

          4. Patients must have demonstrated their willingness to participate in the study and
             comply with the study procedures and required visits.

          5. Patients must have been willing to authorize use and disclosure of protected health
             information collected for the study.

          6. Patients must have had the ability to understand and sign a written consent, which had
             to be signed prior to study specific procedures being performed.

               -  *Abstinence (sexually inactive) was not an acceptable form of contraception;
                  however, abstinent female patients could have been admitted to the study if they
                  agreed, and signed a statement to the effect, that upon becoming sexually active,
                  they would use a condom with spermicide from that time through 30 days beyond
                  completion of the study (Visit 2).

        Exclusion Criteria:

        Patients were excluded from the study if they fulfilled any of the following:

          1. Females who were pregnant or lactating or planning to become pregnant during the study
             period.

          2. Patients with a history of chronic cough of &gt; 3 weeks duration.

          3. Patients with any of the following conditions:

               -  Asthma

               -  Chronic bronchitis

               -  Emphysema

               -  Other chronic pulmonary conditions such as Chronic Obstructive Pulmonary Disease
                  (COPD) or cystic fibrosis (CF), etc.

          4. Patients with known hypersensitivity to GGE.

          5. Patients with temperature greater than 101°F (38.3°C) at Screening/Baseline.

          6. Patients with a serious and/or uncontrolled medical condition (chronic or active liver
             disease, renal impairment, heart disease, diabetes, severe respiratory disease,
             rheumatoid arthritis, current malignancies, immunocompromised conditions or any other
             disease) that in the opinion of the investigator would interfere with the study or
             place the patient at unacceptable risk.

          7. Patients with a history or examination findings of alcohol dependence, alcohol or drug
             abuse or suspected abuse within the past 2 years.

          8. Patients who had participated in a study of an investigational drug within 30 days
             prior to the Screening/Baseline visit.

          9. Patients who in the opinion of the investigator were unable to comply fully with the
             study requirements.

         10. Related to persons involved directly or indirectly with the conduct of this study
             [i.e., investigator, sub-investigators, study coordinators, other study personnel,
             employees of Reckitt Benckiser or Ecron AcuNova Ltd. (EAL), formerly known as Manipal
             Acunova Limited (MAL) and the families of each].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <results_first_submitted>November 19, 2018</results_first_submitted>
  <results_first_submitted_qc>February 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2019</results_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guaifenesin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is a multicentric study conducted in 9 study centres across 7 cities in India.</recruitment_details>
      <pre_assignment_details>A total of 554 subjects were screened, 552 subjects enrolled and 550 of them completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mucinex™</title>
          <description>Subjects received a twice daily dose of Mucinex™ 600 mg Guaifenesin extended-release bi-layer tablets every 12hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="552"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="550"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mucinex™</title>
          <description>Subjects received a twice daily dose of Mucinex™ 600 mg Guaifenesin extended-release bi-layer tablets every 12hours</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="552"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="15.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160.8" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kgs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="11.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="552"/>
                  </measurement_list>
                </category>
                <category>
                  <title>others</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events (AEs), Type of AE(s) and Frequency of AE(s)</title>
        <description>Treatment Emergent Adverse Event (TEAE) are events occurring after the first dose of study medication.
Frequency of AE(s) - the total Number of Events
Type of AE(s) - Serious TEAE and Non serious TEAE</description>
        <time_frame>Up to Day 9</time_frame>
        <population>Safety Population: All patients enrolled in the study were included for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Mucinex™</title>
            <description>Subjects received a twice daily dose of Mucinex™ 600 mg Guaifenesin extended-release bi-layer tablets every 12hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs), Type of AE(s) and Frequency of AE(s)</title>
          <description>Treatment Emergent Adverse Event (TEAE) are events occurring after the first dose of study medication.
Frequency of AE(s) - the total Number of Events
Type of AE(s) - Serious TEAE and Non serious TEAE</description>
          <population>Safety Population: All patients enrolled in the study were included for safety analyses.</population>
          <units>Number of Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Emergent Adverse Event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Affected With Adverse Events</title>
        <description>Proportion of patients with AE(s) - Number of Subjects affected with Events</description>
        <time_frame>Up to Day 9</time_frame>
        <population>Safety Population: All patients enrolled in the study were included for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Mucinex™</title>
            <description>Subjects received a twice daily dose of Mucinex™ 600 mg Guaifenesin extended-release bi-layer tablets every 12hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Affected With Adverse Events</title>
          <description>Proportion of patients with AE(s) - Number of Subjects affected with Events</description>
          <population>Safety Population: All patients enrolled in the study were included for safety analyses.</population>
          <units>Number of Subjects affected with Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events by Severity, Seriousness and the Relationship of AE(s) to Treatment</title>
        <description>Intensity determined. Mild = AE did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Relationship to Investigational Medicinal Products (IMP) Unassessable/Unclassified = Insufficient information to be able to make an assessment Conditional/ Unclassified = Insufficient information to make an assessment at present Unrelated = No possibility that the AE was caused by the IMP Unlikely = Slight, but remote, chance that the AE was caused by the IMP, but the balance of judgment was that it was most likely not due to the IMP.
Possible = Reasonable suspicion that the AE was caused by the IMP Probable = Most likely that the AE was caused by the IMP Certain = AE was definitely caused by the IMP</description>
        <time_frame>Up to Day 9</time_frame>
        <population>Safety Population: All patients enrolled in the study were included for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Mucinex™</title>
            <description>Subjects received a twice daily dose of Mucinex™ 600 mg Guaifenesin extended-release bi-layer tablets every 12hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events by Severity, Seriousness and the Relationship of AE(s) to Treatment</title>
          <description>Intensity determined. Mild = AE did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Relationship to Investigational Medicinal Products (IMP) Unassessable/Unclassified = Insufficient information to be able to make an assessment Conditional/ Unclassified = Insufficient information to make an assessment at present Unrelated = No possibility that the AE was caused by the IMP Unlikely = Slight, but remote, chance that the AE was caused by the IMP, but the balance of judgment was that it was most likely not due to the IMP.
Possible = Reasonable suspicion that the AE was caused by the IMP Probable = Most likely that the AE was caused by the IMP Certain = AE was definitely caused by the IMP</description>
          <population>Safety Population: All patients enrolled in the study were included for safety analyses.</population>
          <units>Number of Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Emergent Adverse Event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Possible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP - Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP - Conditional/Unclassified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Unassessable/Unclassifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Assessment of the Study Medication by End of Study Patient Questionnaire</title>
        <description>End of Study Patient Questionnaire is a questionnaire provided to the patients for overall assessment of the study medication at the end of study visit.
Satisfied(stfd) Dissatisfied(Dstfd)</description>
        <time_frame>Up to Day 9</time_frame>
        <population>Safety Population: All patients enrolled in the study were included for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Mucinex™</title>
            <description>Subjects received a twice daily dose of Mucinex™ 600mg Guaifenesin extended-release bi-layer tablets every 12hours</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Assessment of the Study Medication by End of Study Patient Questionnaire</title>
          <description>End of Study Patient Questionnaire is a questionnaire provided to the patients for overall assessment of the study medication at the end of study visit.
Satisfied(stfd) Dissatisfied(Dstfd)</description>
          <population>Safety Population: All patients enrolled in the study were included for safety analyses.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improvement of Chest Congestion: Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Chest Congestion: Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Chest Congestion: Mostly Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Chest Congestion: Not Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Chest Congestion: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Chesty Cough: Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Chesty Cough: Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Chesty Cough: Mostly Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Chesty Cough: Not Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Chesty Cough: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Improvement: During 1st Day of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Improvement: At 2 Days Of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Improvement: Within 3 Days of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Improvement: More than 3 Days of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Improvement: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosing easy to take / convenient: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosing easy to take / convenient: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosing easy to take / convenient: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective to Treat Chest congestion:Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective to Treat Chest congestion:Somewhat Stfd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective to Treat Chest congestion:Somewhat Dstfd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective to Treat Chest congestion: Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective to Treat Chest congestion: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective to Treat Chesty cough: Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective to Treat Chesty cough:Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective to Treat Chesty cough: Somewhat Dstfd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective to Treat Chesty cough: Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective to Treat Chesty cough: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recommend to Family and friends: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recommend to Family and friends: Maybe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recommend to Family and friends: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recommend to Family and friends: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucinex as first choice</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucinex as top two options</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucinex as alternative, But not primary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Assessment of the Study Medication by End of Study Investigator Questionnaire</title>
        <description>End of Study Investigator Questionnaire is a questionnaire provided at the end of study visit to the investigator (or sub-investigator as applicable) for overall assessment of the study medication across all patients treated by them.
End of study investigator questionnaire was collected from 9 investigators.
Mostly Satisfied(MS) Satisfied(Stfd) Very Satisfied(VS) Chest Congestion(CC) Chesty Cough(CCO) Difference(Diff) Between(b/w) Somewhat Agree(SA) Strongly Agree(StA) Upper respiratory tract infection(URTI) Optimal dosage(Opt dos) Cough preparations Available(CPA)</description>
        <time_frame>Up to Day 9</time_frame>
        <population>Safety Population: All patients enrolled in the study were included for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Mucinex™</title>
            <description>Subjects received a twice daily dose of Mucinex™ 600 mg Guaifenesin extended-release bi-layer tablets every 12hours</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Assessment of the Study Medication by End of Study Investigator Questionnaire</title>
          <description>End of Study Investigator Questionnaire is a questionnaire provided at the end of study visit to the investigator (or sub-investigator as applicable) for overall assessment of the study medication across all patients treated by them.
End of study investigator questionnaire was collected from 9 investigators.
Mostly Satisfied(MS) Satisfied(Stfd) Very Satisfied(VS) Chest Congestion(CC) Chesty Cough(CCO) Difference(Diff) Between(b/w) Somewhat Agree(SA) Strongly Agree(StA) Upper respiratory tract infection(URTI) Optimal dosage(Opt dos) Cough preparations Available(CPA)</description>
          <population>Safety Population: All patients enrolled in the study were included for safety analyses.</population>
          <units>Number of investigator</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment outcome with URTIs taking Mucinex: MS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment outcome with URTIs taking Mucinex: Stfd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment outcome with URTIs taking Mucinex: VS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient satisfaction with the treatment of CC: NS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient satisfaction with the treatment of CC:Stfd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient satisfaction with the treatment of CC: VS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient satisfaction with the treatment of CCO: MS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient satisfaction with treatment of CCO:Stfd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient satisfaction with the treatment of CCO: VS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Improvements: At 2 Days Of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Improvements:Within 3 Days of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Diff b/w CC &amp; CCO congestion: CC first</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Diff b/w CC &amp; CCO congestion:Cough first</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment recommend for CC with URTI Patient:Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment recommend for CC with URTI Patient: SA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment recommend for CC with URTI Patient: StA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opt dos for treating CC compare to other CPA: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opt dos for treating CC compare to other CPA: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to End of Study (Day 9)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mucinex™</title>
          <description>Subjects received a twice daily dose of Mucinex™ 600 mg Guaifenesin extended-release bi-layer tablets every 12hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="552"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="552"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="552"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="552"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="552"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="552"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="552"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="552"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="552"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="552"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="552"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="552"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director, Clinical Research</name_or_title>
      <organization>Reckitt Benckiser Inc.</organization>
      <email>clinicalrequests@rb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

